ReviewWorld journal of gastroenterology2014
Current progress toward eradicating Helicobacter pylori in East Asian countries: differences in the 2013 revised guidelines between China, Japan, and South Korea.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02317445 (Beijing Tiantan Hospital,Capital Medical University.), which is not on this map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Beijing Tiantan Hospital,Capital Medical University.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effectiveness of eradication therapy for Helicobacter pylori infection in Africa: a systematic review and meta-analysis.BMC gastroenterology · 2023Pooled it
- Pooled it
- Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication.British journal of clinical pharmacology · 2022Trial
- International trends in cancer mortality revisited: Japan's site-specific progress and remaining challenges until 2024.Japanese journal of clinical oncology · 2026Article
- Effects of fucoidan and synbiotics supplementation during bismuth quadruple therapy ofFrontiers in nutrition · 2024Article
- Prospective Study of Vonoprazan-Based First-Line Triple Therapy with Amoxicillin and Metronidazole for Clarithromycin-ResistantJournal of clinical medicine · 2023Article
- Management ofGut and liver · 2022Review
- Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects.Translational and clinical pharmacology · 2020Article
- Efficacy of Vonoprazan for Helicobacter pylori Eradication.Internal medicine (Tokyo, Japan) · 2020Review
- Initial Trials With Susceptibility-Based and Empiric Anti-Frontiers in pharmacology · 2019Article
- Clinical Outcomes of Patients with Non-ulcer and Non-variceal Upper Gastrointestinal Bleeding: A Prospective Multicenter Study of Risk Prediction Using a Scoring System.Digestive diseases and sciences · 2018Article
- Characteristics of Helicobacter pylori-seropositive subjects according to the stool antigen test findings: a prospective study.The Korean journal of internal medicine · 2018Article
- Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.Annals of clinical microbiology and antimicrobials · 2018Observational
- Deep learning analyzes Helicobacter pylori infection by upper gastrointestinal endoscopy images.Endoscopy international open · 2018Article
- Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature.Digestive diseases and sciences · 2017Review
- Impact of health insurance coverage forBMJ open · 2017Observational
- Effects ofJournal of clinical medicine research · 2016Article
- Using Foreign Virtual Patients With Medical Students in Germany: Are Cultural Differences Evident and Do They Impede Learning?Journal of medical Internet research · 2016Article
- Systematic review and meta-analysis: Multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events.United European gastroenterology journal · 2016Article
- Recent developments and innovations in gastric cancer.World journal of gastroenterology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New 2013 guidelines on Helicobacter pylori (H. pylori) infection have been published in China, Japan, and South Korea. Like the previous ones, these new guidelines differ between the three countries with regard to the indications for H. pylori eradication, diagnostic methods, and treatment regimens. The most profound change among all of the guidelines is that the Japanese national health insurance system now covers the expenses for all infected subjects up to second-line treatment. This makes the Japanese indications for eradication much wider than those in China and South Korea. With regard to the diagnosis, a serum H. pylori antibody test is not recommended in China, whereas it is considered to be the most reliable method in Japan. A decrease relative to the initial antibody titer of more than 50% after 6-12 mo is considered to be the most accurate method for determining successful eradication in Japan. In contrast, only the urea breath test is recommended after eradication in China, while either noninvasive or invasive methods (except the bacterial culture) are recommended in South Korea. Due to the increased rate of antibiotics resistance, first-line treatment is omitted in China and South Korea in cases of clarithromycin resistance. Notably, the Japanese regimen consists of a lower dose of antibiotics for a shorter duration (7 d) than in the other countries. There is neither 14 d nor bismuth-based regimen in the first-line and second-line treatment in Japan. Such differences among countries might be due to differences in the approvals granted by the governments and national health insurance system in each country. Further studies are required to achieve the best results in the diagnosis and treatment of H. pylori infection based on cost-effectiveness in East Asian countries.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.